Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies

Journal of Virological Methods

Volumn 167, Issue 1, 2010, Pages 10-16

  Batra, Gaurav ^a   Raut, Rajendra ^a   Dahiya, Satinder ^a   Kamran, Neha ^a   Swaminathan, Sathyamangalam ^a   Khanna, Navin ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Dengue virus; Envelope domain III; Pichia pastoris; Subunit vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; ENVELOPE PROTEIN; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLONE; CONTROLLED STUDY; DENGUE VIRUS 2; FUNGAL STRAIN; GENE EXPRESSION; IMMUNIZATION; IMMUNOBLOTTING; INSECT CELL; MAMMAL CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PICHIA PASTORIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SEROTYPE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE VACCINES; DENGUE VIRUS; MANNITOL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; OLEIC ACIDS; PICHIA; PLAQUE ASSAY; SEQUENCE ANALYSIS, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

DENGUE VIRUS; DENGUE VIRUS GROUP; DENGUE VIRUS TYPE 2; MUS; PICHIA PASTORIS;

EID: 77953026557     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.03.002     Document Type: Article

References (38)

1. Apt D., Raviprakash K., Brinkman A., Semyonov A., Yang S., Skinner C., Diehl L., Lyons R., Porter K., Punnonen J. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 2006, 24:335-344.
2. Bernardo L., Fleitas O., Pavón A., Hermida L., Guillén G., Guzman M.G. Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin. Vaccine Immunol. 2009, 16:1829-1831.
3. Blaney J.E., Matro J.M., Murphy B.R., Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in Rhesus monkeys. J. Virol. 2005, 79:5516-5528.
4. Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., Février M., Bedouelle H., Schwartz O., Desprès P., Tangy F. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl. Trop. Dis. 2007, 1:e96.
5. Chin J.F.L., Chu J.J.H., Ng M.L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007, 9:1-6.
6. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., Putnak J.R., Ivy J.M., McDonell M., Bignami G.S., Peters I.D., Leung J., Weeks-Levy C., Nakano E.T., Humphreys T. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28:2705-2715.
7. Crill W.D., Roehrig R.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 2001, 75:7769-7773.
8. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., Khanna N. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg. 2008, 79:353-363.
9. Gromowski G.D., Barrett N.D., Barrett A.D.T. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 2008, 82:8828-8837.
10. Gubler, D.J., Kuno, G., Markoff, L., 2007. Flaviviruses, in: Knipe, D.M., Howley, P.M. (Eds.-in chief), Fields Virology, 5th edition. Wolters Kluwer and Lippincott Williams & Wilkins, Philadelphia, pp. 1153-1252.
11. Gurramkonda C., Adnan A., Gäbel T., Lünsdorf H., Ross A., Nemani S.K., Swaminathan S., Khanna N., Rinas U. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of hepatitis B surface antigen. Microb. Cell Fact. 2009, 8:13. 10.1186/1475-2895-8-13.
12. Guzman M.G., Hermida L., Bernardo L., Ramirez R., Guillén G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev. Vaccines 2010, 9:137-147.
13. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 2003, 60:421-467.
14. Hermida L., Rodríguez R., Lazo L., Bernardo L., Silva R., Zulueta A., López C., Martín J., Valdes I., del Rosario D., Guillén G., Guzmán M.G. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol. Appl. Biochem. 2004, 39:107-114.
15. Hung J.J., Hsieh M.T., Young M.J., Kao C.L., King C.C., Chang W. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J. Virol. 2004, 78:378-388.
16. Innis B.L. Antibody responses to dengue virus infection. Dengue and Dengue Hemorrhagic Fever 1997, 221-243. CAB International, New York. D.J. Gubler, G. Kuno (Eds.).
17. Jaiswal S., Khanna N., Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type-2 envelope domain III protein in Escherichia coli. Protein Exp. Purif. 2004, 33:80-91.
18. Kelly E.P., Greene J.J., King A.D., Innis B.L. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 2000, 18:2549-2559.
19. Khanam S., Etemad B., Khanna N., Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am. J. Trop. Med. Hyg. 2006, 74:266-277.
20. Khanam S., Pilankatta R., Khanna N., Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009, 27:6011-6021.
21. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., Saluzzo J.F. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24:1238-1241.
22. Kuhn R.J., Zhang W., Rossman M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., Strauss J.H. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108:717-725.
23. Macauley-Patrick S., Fazenda M.L., McNeil B., Harvey L.M. Heterologous protein production using Pichia pastoris expression system. Yeast 2005, 22:249-270.
24. Morrison D., Legg T.J., Billings C.W., Rorrat R., Yoksa S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in Flavivirus-naive adults. J. Infect. Dis. 2010, 201:370-377.
25. Muné M., Rodríguez R., Ramírez R., Soto Y., Sierra B., Roche R.R., Marquez G., Garcia J., Guillén G., Guzmán M.G. Carboxy-terminally truncated dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to dengue 4 virus challenge in mice. Arch. Virol. 2003, 148:2267-2273.
26. Pierson T.C., Diamond M.S. Molecular mechanisms of antibody-mediated neutralization of flavivirus infection. Expert Rev. Mol. Med. 2009, 10:e12.
27. Ramanathan M.P., Kuo Y.C., Selling B.H., Li Q., Sardesai N.Y., Kim J.J., Weiner D.B. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 2009, 27:6444-6453.
28. Raviprakash K., Wang D., Ewing D., Holman D.H., Block K., Woraratanadharm J., Chen L., Hayes C., Dong J.Y., Porter K. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in Rhesus monkeys against all four serotypes of dengue virus. J. Virol. 2008, 82:6927-6934.
29. Saejung W., Fujiyama K., Takasaki T., Ito M., Hori K., Malasit P., Watanabe Y., Kurane I., Seki T. Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine 2007, 25:6646-6654.
30. Simmons M., Murphy G.S., Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 2001, 65:159-161.
31. Simmons M., Nelson W.M., Wu S.J., Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 1998, 58:655-662.
32. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., Roehrig J.T., Gromowski G.D., Barrett A.D., Fremont D.H., Diamond M.S. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 2007, 81:12816-12826.
33. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., Vaughn D.W., Thomas S.J., Kanesa-Thasan N., Innis B.L., Edelman R. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-näive adults. Hum. Vaccines 2009, 5:33-40.
34. Suzuki R., Winkelmann E.R., Mason P.W. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J. Virol. 2009, 83:1870-1880.
35. Swaminathan S., Khanna N. Dengue: recent advances in biology and current status of translational research. Curr. Mol. Med. 2009, 9:152-173.
36. Trirawatanapong T., Chandran B., Putnak R., Padmanabhan R. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 1992, 116:139-150.
37. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5:518-528.
38. Zulueta A., Martín J., Hermida L., Alvarez M., Valdés I., Prado I., Chinea G., Rosario D., Guillén G., Guzmán M.G. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 2006, 121:65-73.